BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34536775)

  • 21. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
    Hu T; Gao Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma.
    Ramirez E; Singh RR; Kunkalla K; Liu Y; Qu C; Cain C; Multani AS; Lennon PA; Jackacky J; Ho M; Dawud S; Gu J; Yang S; Hu PC; Vega F
    Leuk Res; 2012 Oct; 36(10):1267-73. PubMed ID: 22809693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
    Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
    Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial-Mesenchymal Transition.
    Kong F; Sun T; Kong X; Xie D; Li Z; Xie K
    Clin Cancer Res; 2018 May; 24(10):2440-2451. PubMed ID: 29367428
    [No Abstract]   [Full Text] [Related]  

  • 25. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
    Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
    Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
    Fiskus W; Mill CP; Perera D; Birdwell C; Deng Q; Yang H; Lara BH; Jain N; Burger J; Ferrajoli A; Davis JA; Saenz DT; Jin W; Coarfa C; Crews CM; Green MR; Khoury JD; Bhalla KN
    Leukemia; 2021 Sep; 35(9):2621-2634. PubMed ID: 33654205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
    Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
    Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
    Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
    Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
    Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
    J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. METTL3 enhances the effect of YTHDF1 on NEDD1 mRNA stability by m6A modification in diffuse large B-cell lymphoma cells.
    Feng L; Yan Q; Pan H; Shi W
    Immun Inflamm Dis; 2023 Feb; 11(2):e789. PubMed ID: 36840486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
    Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
    Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
    Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
    Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma.
    Cai N; Chen Z; Huang Y; Shao S; Yu H; Wang Y; He S
    Cancer Biol Ther; 2020; 21(3):241-247. PubMed ID: 31731887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
    Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
    J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.